Aims: Mesenchymal stem cells (MSCs) hold significant promise as potential therapeutic candidates following cardiac injury. However, to ensure survival of transplanted cells in ischemic environment, it is beneficial to precondition them with growth factors that play important role in cell survival and proliferation. Aim of this study is to use interleukin-7 (IL-7), a cell survival growth factor, to enhance the potential of rat bone marrow MSCs in terms of cell fusion in vitro and cardiac function in vivo.
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Methods:
Mesenchymal stem cells were transfected with IL-7 gene through retroviral vector. Normal and transfected MSCs were co-cultured with neonatal cardiomyocytes (CMs) and cell fusion was analyzed by flow cytometry and fluorescence microscopy. These MSCs were also transplanted in rat model of myocardial infarction (MI) and changes at tissue level and cardiac function were assessed by histological analysis and echocardiography, respectively.
Results: Co-culture of IL-7 transfected MSCs and CMs showed significantly higher (P < 0.01) number of fused cells as compared to normal MSCs. Histological analysis of hearts transplanted with IL-7 transfected MSCs showed significant reduction (P < 0.001) in infarct size and better preservation (P < 0.001) of left ventricular wall thickness as compared to normal MSCs. Presence of cardiac-specific proteins, α-actinin, and troponin-T showed that the transplanted MSCs were differentiated into cardiomyocytes. Echocardiographic recordings of the experimental group transplanted with transfected MSCs showed significant increase in the ejection fraction and fractional shortening (P < 0.01), and decrease in diastolic and systolic left ventricular internal diameters (P < 0.001) and end systolic and diastolic volumes (P < 0.01 and P < 0.001, respectively).
Conclusion:
Interleukin-7 is able to enhance the fusogenic properties of MSCs and improve cardiac function. This improvement may be attributed to the supportive action of IL-7 on cell proliferation and cell survival contributing to the regeneration of damaged myocardium.
| INTRODUC TI ON
Heart diseases are one of the main causes of morbidity and mortality all over the world particularly in developing countries. 1 
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Another useful strategy for enhancing the survival of transplanted cells is to genetically modify stem cells by over-expressing anti-apoptotic proteins, growth factors or pro-survival genes. 16 It has been demonstrated that survival of various stem cells can be enhanced in the ischemic heart by over-expressing specific genes. 27 Interleukin-7 (IL-7) is known to play an important role in cell survival and proliferation. 28 It is a lymphopoietic growth factor which mediates its action through non receptor tyrosine kinase. This stimulates many downstream cellular pathways resulting in the processes of cell survival, proliferation, and differentiation. 29 Specifically, IL-7
is responsible for the development of lymphocytes and survival of naïve and memory T cells. 28 Moreover, it is a molecule of interest in cancer immunotherapy.
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In this study, rat bone marrow MSCs were transfected with IL-7
gene. These IL-7 transfected MSCs were co-cultured with cardiomyocytes (CMs) to see whether IL-7 enhances the fusion between these two cell types. Role of IL-7 was further explored in vivo after transplanting these transfected MSCs in the rat myocardium infarction model. The results obtained from this study are expected to provide the basis for designing improved cell-based therapeutic approach for cardiac tissue regeneration.
| ME THODS
All animal procedures were carried out according to the international guidelines for care and use of laboratory animals after approval from the local ethical committee. Sprague Dawley (SD) rats of both sexes weighing 200-300 g were used throughout the study.
| Isolation of mesenchymal stem cells (MSCs)
For isolation of MSCs, tibia and femur were aseptically dissected.
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mmol/L sodium pyruvate, and 4 mmol/L L-glutamine, was flushed down the bone cavities using a 26-gauge needle. Culture was maintained at 37°C in a humidified atmosphere containing 5% CO 2 . After 4-5 days, adherent MSCs were separated from non adherent hematopoietic cells by removing the medium.
Cells were sub-cultured when they reached approximately 70%
confluence. MSCs of passages 1 -2 (P1 or P2) were used throughout the study.
| Isolation of neonatal cardiomyocytes (CMs)
Cultures of neonatal cardiomyocytes were prepared from the ventricles of 1-2-day-old SD rats, as described previously. 31 Briefly, whole hearts were excised and immediately transferred to ice-cold PBS, and then to balanced salt solution (20 mmol/L HEPES-NaOH; pH 7.6, 130 mmol/L NaCl, 1 mmol/L NaH 2 PO4, 4 mmol/L glucose, 3 mmol/L KCl). Tissue digestion was performed by excising and mincing the ventricles using 0.05% trypsin-EDTA and incubating the mixture at 37°C. The mixture was centrifuged at 1200 g for 10 minutes at 4°C. Cell pellet was resuspended in DMEM/F12 (1:1) supplemented with FBS (20%), penicillin (100 U/mL), streptomycin (100 μg/ mL), and bovine insulin (1 μg/mL). CMs of passages 1 -2 (P1 or P2)
were used throughout the study.
| Characterization of MSCs and CMs
Mesenchymal stem cells and CMs were characterized respectively for specific cell surface markers and cardiac-specific proteins as previously described. 32 MSCs were characterized for the presence of CD90, CD29, CD44, and CD117, while CD45 was used as negative marker. Characterization of CMs was performed for the presence of cardiac-specific proteins, actinin, cardiac troponin-I, cardiac myosin heavy chain, and GATA-4. Differentiation of MSCs into adipocytes and osteocytes has been previously performed and described in detail elsewhere.
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| Retroviral construction and packaging
Interleukin-7 vector used in this study was custom synthesized by Clonetex systems Inc, Austin, TX, USA. TK-NIH/3T3 derived retrovirus packaging cell line, PT67 (ATCC) was used for viral packaging. Details of construction and packaging of the PLXIN-NeoR/IL-7 retroviral vector are described elsewhere. Cells were analyzed by fluorescence microscope and flow cytometer.
| Quantification of IL-7 by ELISA
Interleukin-7 release in the medium was analyzed in case of both normal and transfected MSCs co-cultured with CMs using rat IL-7 ELISA kit (USCN Life Science, Aachen, Germany) according to the manufacturer's instructions.
| Development of rat model of myocardial infarction (MI)
Rats were anesthetized with an intra-peritoneal (i. was inserted into the trachea and connected to the ventilator. Incision was made, transverse to the sternum, and 4th intercostal space was stretched open by retractor to expose the heart. The left anterior descending coronary artery (LAD) was ligated using prolene suture (Ethicon, Cincinnati, OH, USA). Thoracic cavity and tracheal incision and subsequently the outer skin were closed by prolene suture. Rats were returned to the animal facility and were monitored daily for adequate mobility, grooming, and eating habits.
| Transplantation of MSCs
Animals were divided into 5 groups with 5 animals in each group.
One of the groups, referred to as "control", consisted of normal healthy rats. These rats were kept for the same period of time and in similar condition and evaluated for the functional analysis of the heart. Another group, referred to as "MI", was used for the development of myocardial infarction models but received no cellular therapy. The group, "Sham control" has suture passed through myocardium but LAD artery was not ligated. Remaining two groups were the MI models that received normal and IL-7 transfected MSCs. For cell transplantation, one million MSCs (normal and transfected) were suspended separately in 100 μL sterile PBS and injected using sterile syringe (30G × 5/16″; 0.3 × 8 mm) into the ventricular wall of the heart immediately after the ligation of the coronary artery.
| Evaluation of myocardial infarction and cell therapy
Development of the MI model and the effect of cellular therapy
were assessed through histological analysis and echocardiography.
| Histological analysis
Histological sectioning and staining were done to observe changes at the cellular level. After 4 weeks of surgery and cell transplantation, animals were sacrificed and their hearts were excised. After washing with PBS, heart was cut into two pieces and immersed in Histochoice ™ tissue fixative for post-perfusion fixation for about 1 hour. The isolated hearts were incubated in 100% xylene for 1 hour, then placed in equal volumes of xylene and paraffin at 62°C
for 1 hour and finally transferred to 100% paraffin for 24 hours.
The hearts were embedded in paraffin cassettes and 10 μm thick slices were sectioned using microtome. Slides were placed on hot plates for drying and then processed further for staining either by
Hematoxylin and Eosin (H & E) or Masson's Trichrome as per manu-
facturer's instructions.
To track the transplanted MSCs in the fibrotic area, heart tissue sections were examined under fluorescence microscope.
Immunohistochemical staining was performed according to the method described previously 9,10 for cardiac-specific proteins, α-actinin, and troponin-T to assess cardiomyogenic differentiation of the transplanted MSCs. Images were taken with CCD camera using NIS element AR software. Adobe Photoshop was used to analyze and process the images.
| Echocardiography
Echocardiography was performed to record the functional cardiac parameters after 2 and 4 weeks of surgery. Echocardiographic data were obtained at parasternal short and long axis to measure left ventricular systolic and diastolic internal diameters (LVIDs, LVIDd), ejection fraction (EF), fractional shortening (FS) and end systolic and diastolic volumes (ESV, EDV) as described previously.
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| Statistical analysis
Statistical analysis was performed by Student's t test, one way ANOVA and Bonferroni's post hoc test for multiple comparisons.
Data are presented as means ± standard error of mean (SEM). Values of P < 0.05 were considered statistically significant.
| RE SULTS

| Characterization of MSCs and CMs
Characterization of MSCs showed positive expression for CD90, CD29, CD44, and CD117, and negative expression for CD45
( Figure S1 ). Characterization for CMs showed the presence of cardiac-specific proteins, actinin, cardiac troponin-I, cardiac myosin heavy chain, and GATA-4 ( Figure S2 ).
| Transfection of MSCs with IL-7 gene
Packaging cell line, PT67 showed fibroblast-like morphology in culture ( Figure 1A) . After viral infection, calcium phosphate precipitates were observed ( Figure 1B ). When MSCs were transfected with the packaged retroviral particles, cells were shrunken at the beginning but when normal conditions were restored, they regained normal morphol-
ogy (Figure 1C-D). Optimization and confirmation of IL-7 transfection
showed increased expression of IL-7 gene with maximum increase after 48 hours and subsequent decrease at later time points.
| Co-culture analysis
The 15-day co-culture of IL-7 transfected MSCs and CMs showed significant increase (P < 0.01) in the number of fused cells as compared to normal MSCs (Figure 2A-J) . IL-7 release in the co-culture supernatant was significantly higher (P < 0.001) in the group containing IL-7 transfected MSCs as compared to normal MSCs ( Figure 2K ). when compared with that of the normal control. The rhythmicity of cardiac activity was improved as compared to the MI model with slightly reduced wall thickness ( Figure 5 ).
| D ISCUSS I ON
Despite the continuous advancement and improvement in cellbased therapeutic approaches, there are some major concerns that need to be addressed. Two important issues in the cell-based cardiac regenerative therapy are the ineffective engraftment and reduced ability of the cells to survive within the infarcted myocardium. 34 Regenerative potential of the transplanted stem cells is extremely affected by some very important molecular processes including survival, migration, recruitment and homing at the site of injury, and their subsequent differentiation into the desired cell types, posing a major threat to the transplanted cells. Over-expression of cytokines and growth factors which play important role in cellular differentiation, proliferation, survival, and angiogenesis can improve viability of the transplanted cells and subsequently improve tissue function. 35 Earlier, it has been reported that genetically modified MSCs showed better survival, adhesion, and therapeutic potential as compared to normal MSCs. 36 This includes genetic modifications with cell survival, 27, 37 angiogenic, 38 and antiapoptotic 21,39-44 factors which enhance the potential of stem cells to engraft in the infarcted myocardium and improve cardiac function. Also, stem cell factor is shown to stimulate the recruitment of c-kit + cells into the ischemic area of the heart and reduce the infarct size as well as improve the cardiovascular function in animals. 45 Hypoxic preconditioning was also reported to enhance the differentiation potential of MSCs. [46] [47] [48] In this study, we assessed the effect of IL-7 transfection on the fusion of rat bone marrow MSCs and cardiomyocytes in vitro,
and on their subsequent effect on cardiac function in rat model of myocardial infarction. IL-7 is a lymphopoietic cytokine secreted by thymus and bone marrow and plays an important role in cell survival, proliferation, and differentiation. 29 As cell survival is cardiomyocytes. 52 We have earlier reported that IL-7 transfected
MSCs fuse with renal epithelial cells in vitro. 33 Other studies have
shown that various cytokines and growth factors including IL-3, hematopoietic colony-stimulating factor, TNF-alpha, IFN-gamma were able to improve the fusion potential of stem cells with other cell types. 53, 54 Cytokines and growth factors are generally produced by endogenous cardiac cells in response to stress and injury. These soluble molecules possibly function through paracrine signaling to facilitate stem cell mobilization from bone marrow or tissue to the site of injury, thus promoting tissue regeneration. 55 In order to improve the therapeutic potential of MSCs for cardiac repair, it is important to determine the contribution of various factors in the fusion process so that a rationale for their use in cell therapy can be determined. F I G U R E 5 Echocardiographic evaluation of cardiac function before and after cellular transplantation: Bar diagrams showing the comparison of echocardiographic parameters between myocardial infarction (MI) and normal control, MI and cell transplantation groups, and between the two cell transplantation groups after 2 and 4 wk of ligation and cell transplantation. The echocardiographic parameters recorded were (A) left ventricular systolic internal diameter, (B) left ventricular diastolic internal diameter, (C) percent ejection fraction, (D) percent fractional shortening, (E) end-systolic volume, and (F) end-diastolic volume. Data are presented from M and B/M mode echocardiographic images for the measurement of cardiac parameters as an average of five independent experiments (±SD); level of confidence is *P < 0.05 (where * = P < 0.05, ** = P < 0.01, *** = P < 0.001 and NS = not significant)
| CON CLUS ION
It can be concluded from this study that genetic modification of MSCs with IL-7 results in increased fusion of these MSCs with cardiomyocytes in vitro. Moreover, transfected MSCs were able to restore cardiac function with reduction in infarct size, and increased tissue regeneration.
Increased fusion and cardiac differentiation may be attributed to the role of IL-7 in cell survival, proliferation, and differentiation leading to the enhanced regenerative potential of MSCs in vivo.
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